Alexandria posts growth. Alexandria Pharmaceuticals stock trades at 15.49 times earnings

Published on 10/14/2026 at 04:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alexandria Pharmaceuticals earned EGP 524.80 million in fiscal 2025/2026, up 34.16 percent. A 15.49 P/E values Alexandria Pharmaceuticals stock.

Profit and reporting timeline

Alexandria Pharmaceuticals reported EGP 524.80 million in net income for fiscal 2025/2026, up 34.16 percent.
The latest quarter produced EGP 582.64 million in revenue and EGP 93.56 million in net income.
The board meeting on September 20, 2026 reviewed unaudited indicators for the fiscal year ended June 30, 2026.

AXPH, EGS38341C011, Illustration mit AI erstellt.

Alexandria Pharmaceuticals (ISIN EGS38341C011) reported EGP 524.80 million in net income for fiscal 2025/2026, an increase of 34.16 percent, according to Investing.com PH. The same source lists the latest release on September 28, 2026, with quarterly revenue of EGP 582.64 million, net income of EGP 93.56 million and earnings per share of EGP 18.71. Investing.com PH also lists a price-to-earnings ratio of 15.49, the valuation figure used for Alexandria Pharmaceuticals stock in the headline.

Three reported milestones

On June 30, 2026, Alexandria Pharmaceuticals closed the fiscal period with EGP 524.80 million in net income and EGP 672.50 million in operating income, figures shown in Investing.com PH. The annual figures give the profit increase a clear operating reference, because the same report shows revenue of EGP 3.18 billion for the fiscal year.

On September 20, 2026, the board reviewed unaudited, amended business indicators for the fiscal year ended June 30, 2026, according to FoudaLens. The disclosure identifies Alexandria Pharmaceuticals, ISIN EGS38341C011 and ticker AXPH.CA, linking the board review to the annual figures.

On September 28, 2026, the quarterly release showed revenue of EGP 582.64 million versus EGP 764.88 million in the preceding quarter. Net income also declined from EGP 101.24 million to EGP 93.56 million, making the 34.16 percent annual profit increase more important than the sequential comparison.

What does the quarter mean?

The quarter delivered a 16.06 percent net profit margin, while the annual statement lists a 16.49 percent margin, according to Investing.com PH. That contrast points to a business with strong annual profitability but a softer latest quarter, a distinction that matters when investors assess the 15.49 price-to-earnings ratio.

AXPH listing and investor reference

Alexandria Pharmaceuticals is listed on the Egyptian Exchange under ticker AXPH and operates in the pharmaceuticals sector, according to EGX.news. The listing page identifies the company as Alexandria Company for Pharmaceuticals and Chemical Industries and confirms ISIN EGS38341C011.